StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48−0.05 (-2.17%)

Close on Nov 18, 2026Market cap $304.49MP/E –Yield –

C4 Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

C4 Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$101.42M. For fiscal 2025 it was -$104.99M. The highest annual figure on record is -$34.10M in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$104.99M–
FY2024Dec 31, 2024-$105.32M–
FY2023Dec 31, 2023-$132.49M–
FY2022Dec 31, 2022-$128.18M–
FY2021Dec 31, 2021-$83.89M–
FY2020Dec 31, 2020-$66.34M–
FY2019Dec 31, 2019-$34.10M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.64M–
Q1 FY2026Mar 31, 2026-$25.13M–
Q4 FY2025Dec 31, 2025-$20.49M–
Q3 FY2025Sep 30, 2025-$32.17M–
Q2 FY2025Jun 30, 2025-$26.02M–
Q1 FY2025Mar 31, 2025-$26.32M–
Q4 FY2024Dec 31, 2024-$34.57M–
Q3 FY2024Sep 30, 2024-$24.67M–
Q2 FY2024Jun 30, 2024-$17.72M–
Q1 FY2024Mar 31, 2024-$28.36M–
Q4 FY2023Dec 31, 2023-$34.75M–
Q3 FY2023Sep 30, 2023-$27.04M–
Q2 FY2023Jun 30, 2023-$35.92M–
Q1 FY2023Mar 31, 2023-$34.78M–
Q4 FY2022Dec 31, 2022-$37.19M–
Q3 FY2022Sep 30, 2022-$31.96M–
Q2 FY2022Jun 30, 2022-$27.41M–
Q1 FY2022Mar 31, 2022-$31.62M–
Q4 FY2021Dec 31, 2021-$15.66M–
Q3 FY2021Sep 30, 2021-$24.68M–
Q2 FY2021Jun 30, 2021-$22.58M–
Q1 FY2021Mar 31, 2021-$20.97M–
Q4 FY2020Dec 31, 2020-$21.80M–
Q3 FY2020Sep 30, 2020-$21.84M–
Q2 FY2020Jun 30, 2020-$10.79M–
Q1 FY2020Mar 31, 2020-$11.91M–
Q4 FY2019Dec 31, 2019-$10.02M–
Q3 FY2019Sep 30, 2019-$10.09M–

More C4 Therapeutics figures

See a number that looks wrong?